Takeda (TSE:4502/NYSE:TAK) and Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) today announced that the U.S. Food and Drug Administration (FDA) accepted the New Drug Application (NDA) and ...

Successfully started 216 patients on IBTROZI® (taletrectinib) in the fourth quarter of 2025, for a total of 432 new patient starts since launch in the ...

The ready-to-eat beef jerky items bear best by dates of February 17, 2027 or prior. The following products subject to the public health alert are [ view labels ]: 6-oz. plastic packages containing ...

This roadside attraction has been playing the long game with travelers’ curiosity for decades, and it’s become such an iconic part of Arizona’s quirky landscape that not stopping feels almost ...

Bamahenge has earned its place in the pantheon of great American roadside attractions, right up there with the world’s ...

The Supreme Court’s recent refusal to entertain a PIL seeking minimum wages for domestic workers has triggered strong ...

Commercial launch is on-track for ZUSDURI™, the first and only FDA-approved medication for adults with recurrent low-grade intermediate-risk ...

Global Infrastructure Partners ("GIP"), a part of BlackRock, and the EQT Infrastructure VI fund ("EQT"), along with co-underwriters California Public Employees' Retirement System ("CalPERS") and Qatar ...

Commercial launch is on-track for ZUSDURI, the first and only FDA-approved medication for adults with recurrent low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC); net sales ...